Magnesium oxide to reduce prostate motion.
Recruiting
- Conditions
- 1. Prostate cancer<br />2. radiotherapy.<br />(NLD: prostaatkanker, bestraling).
- Registration Number
- NL-OMON24191
- Lead Sponsor
- niversity Medical Center Utrecht, The Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 184
Inclusion Criteria
Prostate cancer patients scheduled for external beam radiotherapy using fiducial marker-based position verification.
Exclusion Criteria
1. Patients with known severe constipation;
2. Patients who receive laxatives;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main study parameter is the movement of the prostate during a fraction of radiotherapy. The three fiducial markers are being imaged 5 times during one fraction. These 5 images can be used to derive the range of the intrafraction movement of the prostate.
- Secondary Outcome Measures
Name Time Method Toxicity will be measured by the Common Toxicity Criteria (CTC) version 3.0 (Trotti). The physician in attendance will score the complaints before treatment and acute toxicity will be scored weekly during the treatment and four weeks after the treatment. All symptoms will be registered even if they occur only on one single occasion. <br /><br><br /><br /><br>The Quality of Life (QoL) before treatment and after the treatment will be measured by RAND-36 (general health), EORTC QLQ-C30 (+3) (cancer specific) and the EORTC QLQ-PR25 (prostate specific) (Hornbrook, Aaronson, Borghede). The first QoL questionnaire will be hand over to the patient at the department and the second questionnaire will be sent to the patient. <br /><br><br /><br /><br>The amount of gas will be counted by delineation of the gas pockets on the CT-scan and MR-scan before the treatment.<br>